Why the study?
Statin therapy leads to coronary plaque regression, but its relationship with coronary plaque stabilization has not been elucidated.
Does statin therapy increase fibrous cap thickness in coronary plaque as assessed by OCT?
Does statin therapy increase fibrous cap thickness in coronary plaque as assessed by OCT?
Statin therapy significantly increases fibrous cap thickness in coronary plaques as assessed by OCT, providing imaging evidence for plaque stabilization.
Statin therapy increases coronary FCT on OCT; extends plaque stabilization evidence beyond regression and supports OCT endpoints in future trials.
BACKGROUND: Statin therapy has been shown to result in coronary plaque regression, but the relationship between statin use and stabilization of coronary plaque has not been elucidated. We conducted a systematic review and meta-analysis to evaluate the effect of statin therapy on fibrous cap thickness (FCT) on optical coherence tomography (OCT). METHODS AND RESULTS: =0 were identified: mean FCT change was 27.8 µm (for subgroup atorvastatin 5 mg and rosuvastatin), and 61.9 µm (for subgroup atorvastatin 20 mg, fluvastatin 30 mg, and pitavastatin 4 mg). On meta-regression modeling, statin therapy alone explained most of the change in FCT. CONCLUSIONS: Statin therapy induced a significant increase in FCT as assessed on OCT, independent of coronary risk factors and other medications.
No takes yet. Share an insight, caveat, or question.
Ozaki et al. (2019) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: